Transparency Market Research (TMR), a market intelligence company based in the U.S., recently published a market study on the global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market for the period 2014 to 2020. The TMR research report states that the global HPV therapeutics market was worth US$1.40 billion in 2013 and is forecast to be worth US$2.34 billion in 2020, progressing at a 7.7% CAGR during the forecast period of 2014 to 2020. On the other hand, The CMV therapeutics market is poised to grow from US$0.87 billion in 2013 to US$0.92 billion in 2020, exhibiting a less favorable CAGR of 1.5% from 2014 to 2020.The research report “Human Papillomavirus and Cytomegalovirus Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020” is available for sale on the company website.
According to the research report, HPV, which exists in more than 100 strains, causes serious conditions such as benign or malignant forms of cancer and sexually transmitted diseases (STDs), which is driving the global HPV therapeutics market. High seroprevalence, predominantly in developing and underdeveloped nations has increased the occurrence of CMV infection among a larger population pool, which is driving the CMV therapeutics market, as added by TMR analysts.The global HPV therapeutics market is segmented on the basis of drug class, applications, and geographical regions. By drug class, immunomodulators accounted for the largest share of the HPV therapeutics market in 2013 owing to increased efficiency, cost-effectiveness, and non-invasive nature of treatment. Sinecatchins drug class will exhibit the fastest growth during the forecast period.
Application-wise, genital warts accounted as the highest revenue generator for the HPV therapeutics market. This is due to the high number of HPV strains that cause genital warts, which can be easily transmitted through sexual contact.Application, drug class, and pipeline drugs are the criteria based on which the global CMV market is segmented. In the drug class, ganciclovir and valganciclovir are the most prescribed for CMV infections, which collectively account for over 85% of the revenue of the global CMV therapeutics market.Pipeline drugs such as brincidofovir, slated for a 2016 launch, and letermovir for 2018, will overcome the resistance issues for valganciclovir and ganciclovir in HIV patients and hence boost the CMV therapeutics market in the coming years.
Download Complete Healthcare Analytical Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3986
The global HPV and CMV therapeutics market is divided into five broad regions: North America, Europe, South America, Asia Pacific, and Rest of the World. In terms of revenue, North America dominated the global HPV and CMV market in 2013. The North American HPV therapeutics market is driven by a surge in the sexually active population, growing immigrant population, and increase in diagnostic practices. In this region, the CMV therapeutics market is propelled by escalating drug costs, increasing organ transplant procedures, and high risk of STDs.The Asia Pacific and South America regional segments are both expected to witness substantial growth in the HPV and CMV therapeutics market till 2020.
No comments:
Post a Comment